Table 2.
Anthropometric and biochemical parameters at baseline and after 6 weeks of nutraceuticals or control treatment.
| Control (CTR) |
Nutraceuticals (NTR) |
p1 | p2 | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline | After 6 weeks | % Change | Baseline | After 6 weeks | % Change | |||
| Weight (kg) | 85.9 ± 3.7 | 86.4 ± 3.8 | 0.4 ± 0.2 | 85.6 ± 3.7 | 85.7 ± 3.6 | 0.2 ± 0.3 | 0.948 | 0.616 |
| BMI (kg/m2) | 32.4 ± 1.1 | 32.6 ± 1.1 | 0.4 ± 0.2 | 32.2 ± 1.0 | 32.3 ± 1.0 | 0.2 ± 0.3 | 0.936 | 0.616 |
| Waist circumference (cm) | 100.6 ± 2.5 | 100.4 ± 2.6 | −0.3 ± 0.4 | 100.8 ± 2.4 | 100.1 ± 2.3 | −0.5 ± 0.4 | 0.955 | 0.733 |
| Abdominal circumference (cm) | 104.3 ± 2.7 | 104.4 ± 2.6 | 0.1 ± 0.3 | 105.7 ± 2.5 | 104.4 ± 2.4 | −1.0 ± 0.6 | 0.710 | 0.076 |
| Hip circunference (cm) | 111.4 ± 2.3 | 111.2 ± 2.3 | −0.1 ± 0.4 | 111.1 ± 2.3 | 111.6 ± 2.3 | 0.4 ± 0.4 | 0.946 | 0.271 |
| Glucose (mg/dL) | 102.1 ± 4.7 | 108.0 ± 4.7 | 11.4 ± 5.4 | 100.3 ± 3.4 | 104.7 ± 3.7 | 7.26 ± 3.8 | 0.776 | 0.532 |
| HbA1c (%) | 6.5 ± 0.1 | 6.6 ± 0.1 | 1.7 ± 1.2 | 6.5 ± 0.1 | 6.4 ± 0.1 | −0.6 ± 1.2 | 0.910 | 0.181 |
| Total cholesterol (mg/dL) | 170.9 ± 6.5 | 171.8 ± 5.3 | 5.5 ± 4.0 | 171.9 ± 5.9 | 151.5 ± 5.7 | −10.1 ± 2.7 | 0.913 | 0.002 |
| LDL-C (mg/dL) | 86.1 ± 4.6 | 84.9 ± 3.5 | 7.9 ± 5.7 | 90.1 ± 4.8 | 74.1 ± 3.9 | −13.7 ± 3.7 | 0.543 | 0.002 |
| Non-HDL-C (mg/dL) | 113.3 ± 5.3 | 116.4 ± 3.4 | 10.3 ± 4.8 | 115.4 ± 5.0 | 98.3 ± 4.6 | −12.0 ± 3.4 | 0.776 | 0.000 |
| HDL-C (mg/dL) | 54.8 ± 1.9 | 53.0 ± 1.9 | −0.75 ± 3.6 | 53.7 ± 1.6 | 50.7 ± 1.5 | −3.6 ± 2.7 | 0.634 | 0.527 |
| VLDL-C (mg/dL) | 29.7 ± 2.4 | 33.2 ± 1.8 | 24.9 ± 6.0 | 28.3 ± 2.6 | 25.0 ± 1.7 | 5.3 ± 8.1 | 0.704 | 0.054 |
| TG (mg/dL) | 146.1 ± 13.4 | 150.1 ± .12.6 | 10.7 ± 6.2 | 129.8 ± 14.6 | 125.2 ± 7.8 | 16.7 ± 8.5 | 0.413 | 0.564 |
| CPK | 152.4 ± 15.7 | 129.1 ± 13.3 | −10.4 ± 5.9 | 158.0 ± 16.7 | 139.4 ± 14.0 | −0.1 ± 6.8 | 0.807 | 0.254 |
| AST (U/L) | 28.2 ± 1.7 | 27 ± 1.2 | 4.22 ± 3.4 | 30.8 ± 1.4 | 31.0 ± 1.7 | 2.1 ± 3.8 | 0.240 | 0.678 |
| ALT (U/L) | 23.9 ± 2.0 | 24.3 ± 1.6 | 8.5 ± 7.7 | 26.3 ± 1.6 | 28 ± 2.2 | 7.9 ± 5.0 | 0.356 | 0.946 |
| hs-CRP (mg/L) | 2.1 ± 0.3 | 1.4 ± 0.21 | −10.9 ± 9.3 | 2.1 ± 0.3 | 1.2 ± 0.2 | −35.5 ± 5.9 | 0.912 | 0.027 |
| MDA (umol/L) | 2.4 ± 0.2 | 1.7 ± 0.1 | −1.2 ± 11.8 | 2.2 ± 0.1 | 1.8 ± 0.1 | −1.7 ± 11.1 | 0.479 | 0.976 |
| Glutathione peroxidase (U/mL) | 9.5 ± 0.3 | 9.2 ± 0.3 | 3.9 ± 6.1 | 8.5 ± 0.3 | 8.1 ± 0.2 | 1.7 ± 4.18 | 0.666 | 0.299 |
| Glutathione reductase (U/mL) | 0.081 ± 0.003 | 0.084 ± 0.003 | 10.44 ± 5.53 | 0.082 ± 0.004 | 0.083 ± 0.003 | 6.52 ± 4.32 | 0.844 | 0.577 |
| Superoxide dismutase (U/mL) | 9.6 ± 0.2 | 8.2 ± 0.3 | −12.3 ± 3.6 | 9.4 ± 0.2 | 8.2 ± 0.2 | −10.6 ± 3.4 | 0.510 | 0.726 |
| Catalase (U/mL) | 56.9 ± 1.5 | 63.2 ± 2.2 | 14.9 ± 5.1 | 57.0 ± 1.6 | 70.0 ± 2.4 | 26.1 ± 5.2 | 0.984 | 0.128 |
Values are expressed as mean ± SEM (n = 53). Percent changes from baseline were calculated after each treatment. Treatment with nutraceuticals (NTR) consisted of a combined supplementation of fish oil softgels, plant sterol enriched chocolate truffles and green tea. Control treatment (CTR) consisted of soy bean oil softgels, regular dark chocolate truffles and anise tea sachets. p1: probability value obtained by independent samples T-test for baseline values between NTR and CTR. p2: probability value obtained by independent samples T-test between % change after NTR and CTR.
Bold font indicates statistically significant p values.